Company Analysis

Zymeworks Inc. (ZYME)

Nasdaq: ZYME · Pharmaceutical Preparations · Middletown, DE · filing with the SEC since 2022
Grade5.1
◀ Past 5.8● Present 5.1▶ Future 4.4
1 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 2, 2026Mar 5, 2025Mar 6, 2024Mar 7, 2023··
Revenue105,96576,30476,012412,48226,68038,951
Research and development137,000134,621143,619208,596199,752171,203
General and administrative61,51461,50670,44673,35842,56155,216
Total costs and expenses198,514213,414214,065281,954242,313226,419
Operating income-92,549-137,110-138,053130,528-215,633-187,468
Interest income (expense), net13,35419,94119,7053,5961,9655,697
Other income (expense), net51-218291-42118-35
Total non-operating income (expense)-559558-8941,1101,3091,648
Income before income taxes-79,754-116,611-119,242135,234-212,359-180,123
Income tax expense1,3766,084-56810,893-516429
Net income including non-controlling interests··-118,674124,341-211,843-180,552
Net income-81,130-122,695-118,674124,341-211,843-180,552
Net income to common shareholders-81,130-122,695-118,674124,341-211,843-180,552
Earnings per share, basic-1.08-1.62-1.721.91-4.11-3.58
Earnings per share, diluted-1.08-1.62-1.721.90-4.61-3.58
Weighted average shares, basic75,404,89775,846,68168,863,01065,194,77551,553,86950,382,497
Weighted average shares, diluted75,413,39675,878,73868,863,01065,249,18452,131,59650,382,497
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest income (expense), net interest earned less interest paid, outside the businessus-gaap:InterestIncomeExpenseNonoperatingNet
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton ZYME · research, not advice